According to Nova One Advisor, the global next-generation sequencing market size is calculated at USD 17.37 billion in 2026 ...
A 46-year-old man was diagnosed with pleural effusion - a case of fluid accumulation around the lungs. According to his diagnostic tests, he was a confirmed case of stage 4 adenocarcinoma of the lung ...
Genomics offers a foundation for understanding disease, but proteomics reveals invaluable insights by offering a real-time look at protein activity. Proteogenomic studies are advancing thanks to ...
The Global Consumer Genomics Market is primed for growth due to decreasing sequencing costs and rising health awareness, expanding from USD 2.72 Billion in 2025 to USD 8.02 Billion by 2031.
A cancer diagnosis is one of the most dreaded news an individual and their family could receive. In the past, many scientists and clinicians have searched for a definitive cure for cancer. However, ...
Advanced lung cancer inflammation index (ALI) as a prognostic marker for locally advanced and metastatic cancer: A prospective study. Phase II study of disitamab vedotin (RC48) in combination with ...
Even the most straightforward next-generation sequencing (NGS) experiments can be expensive and time-consuming. Thus, it’s a good idea to test your workflow on a few samples to make sure you’ll get ...
Explore decentralized liquid biopsy with SOPHiA GENETICS and MSK-ACCESS®, expanding access, improving outcomes, and ...
TEMPLE CITY, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results